The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Open accessAbstract
BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P=0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“At a median follow-up of 11.2 months, PFS was longer in the talazoparib arm (8.6 versus 5.6 months, HR 0.54; 95% CI 0.41-0.71, P < 0.0001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A. N. J., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazińska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 909
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 895
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 519
Research works printed but not linked: 1
- Turner NC, Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society of Clinical Oncology 2017 Annual Meeting, Chicago, June 2–6, 2017. abstract.
Cited by
Sorted by citations
Items 401–500 of 1,000
Senkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34525 · Cited by 39
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
Adashek, J. J., Jain, R., & Zhang, J. (2019) · Cells · doi:10.3390/cells8080860 · Cited by 40
Leptomeningeal Metastases: New Opportunities in the Modern Era
Wilcox, J. A., Li, M., & Boire, A. A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01261-4 · Cited by 38
Mittal, A., Moltó, C., Tamimi, F., Schlam, I. M., Sammons, S. L., Tolaney, S. M., & Tarantino, P. (2023) · Cancers · doi:10.3390/cancers15072015 · Cited by 41
Watanabe, K., & Seki, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020752 · Cited by 39
Yang, C., Liu, H., Feng, X., Shi, H., Jiang, Y., Li, J., & Tan, J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001586 · Cited by 39
Advancing cancer therapy: new frontiers in targeting DNA damage response
Qian, J., Liao, G., Chen, M., Peng, R., Yan, X., Du, J., Huang, R., Pan, M., Lin, Y., Gong, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1474337 · Cited by 44
Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment
Xu, L., Xu, P., Wang, J., Ji, H., Zhang, L., & Tang, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177202 · Cited by 42
Fang, P. Q., Jagsi, R., He, W., Lei, X. J., Campbell, E. G., Giordano, S. H., & Smith, G. L. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02067 · Cited by 39
Schneeweiß, A., Denkert, C., Fasching, P. A., Fremd, C., Gluz, O., Kolberg‐Liedtke, C., Loibl, S., & Lück, H. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0887-0285 · Cited by 40
The Asian Breast Cancer Cooperative Group, Yeo, W., Ueno, T., Lin, C., Liu, Q., Lee, K.-H., Leung, R. C.-Y., Naito, Y., Park, Y. H., Im, S., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05318-5 · Cited by 39
Self-citationKim, J., Yu, D., Kwon, Y., Lee, K. S., Sim, S. H., Kong, S., Lee, E. S., Park, I. H., & Park, C. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0453 · Cited by 41
Self-citationGupta, M., Iyer, R. V., & Fountzilas, C. K. (2019) · Cancers · doi:10.3390/cancers11121980 · Cited by 40
A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women
Seung, S. J., Traore, A. N., Pourmirza, B., Fathers, K. E., Coombes, M., & Jerzak, K. J. (2020) · Current Oncology · doi:10.3747/co.27.5769 · Cited by 40
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
Taylor, A. M., Chan, D. L. H., Tio, M., Patil, S. M., Traina, T. A., Robson, M. E., & Khasraw, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011395.pub2 · Cited by 39
Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
Lehrer, E. J., Stoltzfus, K. C., Jones, B. M., Gusani, N. J., Walter, V., Wang, M., Trifiletti, D. M., Siva, S., Louie, A. V., & Zaorsky, N. G. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000866 · Cited by 41
Seize the engine: Emerging cell cycle targets in breast cancer
Fuentes‐Antrás, J., Bedard, P. L., & Cescon, D. W. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1544 · Cited by 40
Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
Tacconi, E. M., Badie, S., Gregoriis, G. D., Reisländer, T., Lai, X., Porru, M., Folio, C., Moore, J., Kopp, A., Torres, J. B., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809982 · Cited by 37
Sardesai, S. D., Badawi, M. A., Mrózek, E., Morgan, E., Phelps, M. A., Stephens, J. A., Wei, L., Kassem, M. A. M., Ling, Y., Lustberg, M. B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00895-5 · Cited by 38
Zhao, J., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000710 · Cited by 40
Gandhi, S., Oshi, M., Murthy, V., Repasky, E. A., & Takabe, K. (2021) · Cancers · doi:10.3390/cancers13112559 · Cited by 38
Emerging treatment strategies for metastatic triple-negative breast cancer
Huppert, L. A., Gümüşay, Ö., & Rugo, H. S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221086916 · Cited by 42
Self-citationMeijer, T. G., Nguyen, L., van Hoeck, A., Sieuwerts, A. M., Verkaik, N. S., Ladan, M. M., Ruigrok-Ritstier, K., van Deurzen, C. H. M., van de Werken, H. J. G., Lips, E. H., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02363-1 · Cited by 36
Reinisch, M., Bruzas, S., Spoenlein, J., Shenoy, S. S., Traut, A., Harrach, H., Chiari, O., Cremer, E., Ataseven, B., Gubelt, L., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231200454 · Cited by 39
Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316607 · Cited by 45
Ke, Q., Mu, Y., Hu, Y., Li, J., & Liu, J. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1611055 · Cited by 43
Singer, C. F., Balmañà, J., Bürki, N., Delaloge, S., Filieri, M. E., Gerdes, A.-M., Grindedal, E. M., Han, S., Johansson, O., Kaufman, B., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.007 · Cited by 37
Criscuolo, D., Morra, F., Giannella, R., Cerrato, A., & Celetti, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123100 · Cited by 40
Lee, J. S., Yost, S. E., Blanchard, S., Schmolze, D. B., Yin, H. H., Pillai, R. K., Robinson, K., Tang, A., Martínez, N., Portnow, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1202-4 · Cited by 37
Lama-Sherpa, T. D., & Shevde, L. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0665 · Cited by 37
Exman, P., Mallery, R. M., Lin, N., & Parsons, H. A. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0139-1 · Cited by 37
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Ricci, A. D., Rizzo, A., Bonucci, C., Tober, N., Palloni, A., Mollica, V., Maggio, I., Deserti, M., Tavolari, S., & Brandi, G. (2020) · Medicines · doi:10.3390/medicines7090054 · Cited by 37
Kim, K. B., Soroceanu, L., de Semir, D., Millis, S. Z., Ross, J. S., Vosoughi, E., Dar, A. A., Nosrati, M., Desprez, P., Ice, R. J., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.024 · Cited by 38
van Wijk, L. M., Nilas, A. B., Vrieling, H., & Vreeswijk, M. P. G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2020102 · Cited by 41
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
Solís, M. C., Vethencourt, A., & Pernas, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01339-4 · Cited by 38
Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: Talazoparib
McCann, K. E. (2019) · Future Oncology · doi:10.2217/fon-2018-0751 · Cited by 35
State of art of advanced triple negative breast cancer
Khosravi‐Shahi, P., Cabezón‐Gutiérrez, L., & Salcedo, M. I. A. (2019) · The Breast Journal · doi:10.1111/tbj.13369 · Cited by 36
Thomssen, C., Lüftner, D., Untch, M., Haidinger, R., Würstlein, R., Harbeck, N., Augustin, D., Briest, S., Ettl, J., Fasching, P. A., et al. (2020) · Breast Care · doi:10.1159/000505957 · Cited by 37
Self-citationWang, Z., Xu, C., Diplas, B. H., Moure, C. J., Chen, C.-P. J., Chen, L. H., Du, C., Zhu, H., Greer, P. K., Zhang, L., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0507 · Cited by 36
Genomic Signatures in Luminal Breast Cancer
Puppe, J., Seifert, T., Eichler, C., Pilch, H., Mallmann, P. K., & Malter, W. (2020) · Breast Care · doi:10.1159/000509846 · Cited by 37
Lui, G. Y. L., Shaw, R. C., Schaub, F. X., Stork, I. N., Gurley, K. E., Bridgwater, C., Diaz, R. L., Rosati, R., Swan, H. A., Ince, T. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102988 · Cited by 38
van der Wijngaart, H., Hoes, L. R., Henegouwen, J. M. V. B., van der Velden, D. L., Zeverijn, L. J., Roepman, P., van Werkhoven, E., de Leng, W. W. J., Jansen, A. M. L., Mehra, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1104 · Cited by 38
Metastatic disease to the liver: Locoregional therapy strategies and outcomes
Zane, K. E., Cloyd, J. M., Mumtaz, K., Wadhwa, V., & Makary, M. S. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i9.725 · Cited by 39
Wu, R., Patel, A. P., Tokumaru, Y., Asaoka, M., Oshi, M., Yan, L., Ishikawa, T., & Takabe, K. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06552-0 · Cited by 36
Schettini, F., Venturini, S., Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., Placido, P. D., Harbeck, N., Lüftner, D., Denys, H. G., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102468 · Cited by 37
Garber, H. R., Raghavendra, A. S., Lehner, M., Qiao, W., Gutierrez‐Barrera, A. M., Tripathy, D., Arun, B., & Ibrahim, N. K. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00407-z · Cited by 35
DNA damage and metabolic mechanisms of cancer drug resistance
Tiek, D. M., & Cheng, S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.148 · Cited by 39
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
Ivanova, M. D., Porta, F. M., Giugliano, F., Frascarelli, C., Sajjadi, E., Venetis, K., Cursano, G., Mazzarol, G., Guerini‐Rocco, E., Curigliano, G., et al. (2023) · Genes · doi:10.3390/genes14061160 · Cited by 37
Grinda, T., Antoine, A., Jacot, W., Cottu, P. H., Rouge, T. D. L. M., Frenel, J., Mailliez, A., Dalenc, F., Gonçalvès, A., Clatot, F., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.023 · Cited by 35
Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer
Zelli, V., Compagnoni, C., Cannita, K., Capelli, R., Capalbo, C., Nolfi, M. D. V., Alesse, E., Zazzeroni, F., & Tessitore, A. (2020) · Microarrays · doi:10.3390/ht9010001 · Cited by 40
Biologic therapy for advanced breast cancer: recent advances and future directions
Tarantino, P., Morganti, S., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1752176 · Cited by 38
Li, H., Liu, R., Shao, B., Ran, R., Song, G., Wang, K., Shi, Y., Liu, J., Hu, W., Chen, F., et al. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.03.08 · Cited by 35
Self-citationFarshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 39
Hacking, S. M., Yakirevich, E., & Wang, Y. (2022) · Cancers · doi:10.3390/cancers14143469 · Cited by 40
Li, W.-H., Wang, F., Song, G.-Y., Yu, Q., Du, R.-P., & Xu, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1198948 · Cited by 37
Systemic Therapy in Breast Cancer
Corti, C., Batra-Sharma, H., Kelsten, M. F., Shatsky, R. A., Garrido-Castro, A. C., & Gradishar, W. J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432442 · Cited by 38
Systemic Therapy of Central Nervous System Metastases of Breast Cancer
Leone, J. P., & Lin, N. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0802-6 · Cited by 33
Bartoletti, M., Pelizzari, G., Gerratana, L., Bortot, L., Lombardi, D., Nicoloso, M. S., Scalone, S., Giorda, G., Baldassarre, G., Sorio, R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113805 · Cited by 34
Holánek, M., Selingerová, I., Bílek, O., Kazda, T., Fabián, P., Foretová, L., Zvaríková, M., Obermannova, R. L., Koloušková, I., Coufal, O., et al. (2021) · Cancers · doi:10.3390/cancers13071586 · Cited by 34
Gelmon, K. A., Fasching, P. A., Couch, F. J., Balmañà, J., Delaloge, S., Labidi‐Galy, S. I., Bennett, J., McCutcheon, S., Walker, G., O’Shaughnessy, J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.029 · Cited by 34
Self-citationHobbs, E. A., Litton, J. K., & Yap, T. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1952181 · Cited by 35
Self-citationThill, M., Friedrich, M., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2021) · Breast Care · doi:10.1159/000516420 · Cited by 34
Kinj, R., Muggeo-Bertin, E., Schiappacasse, L., Bourhis, J., & Herrera, F. G. (2022) · Cancers · doi:10.3390/cancers14051152 · Cited by 34
Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes
Onji, H., & Murai, J. (2022) · Cancer Science · doi:10.1111/cas.15477 · Cited by 38
Theranostics for Triple-Negative Breast Cancer
Choi, H. R., & Kim, K. (2023) · Diagnostics · doi:10.3390/diagnostics13020272 · Cited by 38
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 35
Lang, Y., Chai, Q., Tao, W., Liao, Y., Liu, X., & Wu, B. (2023) · The Breast · doi:10.1016/j.breast.2023.02.003 · Cited by 33
Tung, N., Dougherty, K. C., Gatof, E. S., DeLeonardis, K., Hogan, L., Tukachinsky, H., Gornstein, E. L., Oxnard, G. R., McGregor, K., & Keller, R. B. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00429-1 · Cited by 35
Güldenpfennig, A., Hopp, A.-K., Muskalla, L., Manetsch, P., Raith, F., Hellweg, L., Doerdelmann, C., Pedrioli, D. M. L., Johnsson, K., Superti‐Furga, G., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad659 · Cited by 33
Bustos, M. A., Yokoe, T., Shoji, Y., Kobayashi, Y., Mizuno, S., Murakami, T., Zhang, X., Sekhar, S. C., Kim, S., Ryu, S., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01151-y · Cited by 33
Peng, S., Long, M., Chen, Q.-S., Yin, Z., Zeng, C., Zhang, W., Wen, Q., Zhang, X., Ke, W., & Wu, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02418-8 · Cited by 38
Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer
Eskiler, G. G., Çeçener, G., Egelí, Ü., & Tunca, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29552 · Cited by 32
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Akçakanat, A., Zheng, X., Pico, C. X. C., Kim, T., Chen, K., Korkut, A., Şahin, A. A., Holla, V. R., Tarco, E., Singh, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4048 · Cited by 33
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
An overview of genetic services delivery for hereditary breast cancer
Reid, S., Spalluto, L. B., Lang, K., Weidner, A. E., & Pal, T. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06478-z · Cited by 33
Voutsadakis, I. A., & Stravodimou, A. (2023) · Anticancer Research · doi:10.21873/anticanres.16241 · Cited by 37
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Grinda, T., Rassy, E., & Pistilli, B. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01072-5 · Cited by 34
Immunotherapy in Triple-Negative Breast Cancer: Present and Future
Kim, I., Sanchez, K. G., McArthur, H. L., & Page, D. B. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00345-z · Cited by 33
Shah, A. N., Metzger, O., Bartlett, C. H., Liu, Y., Huang, X., & Cristofanilli, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0729 · Cited by 35
Pont, M., Marqués, M., & Sorolla, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413518 · Cited by 39
New Treatment Approaches for Triple-Negative Breast Cancer
Riaz, F., Gruber, J. J., & Telli, M. L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-481154 · Cited by 32
Dissecting PARP inhibitor resistance with functional genomics
Pettitt, S. J., & Lord, C. J. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.03.001 · Cited by 32
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy
Gilmore, E. S., McCabe, N., Kennedy, R. D., & Parkes, E. E. (2019) · Journal of Oncology · doi:10.1155/2019/4325105 · Cited by 32
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer
Cragun, D. L., Weidner, A. E., Tezak, A. L., Zuniga, B., Wiesner, G. L., & Pal, T. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7546 · Cited by 32
Fan, Y., Ying, H., Wu, X., Chen, H., Hu, Y., Zhang, H., Wu, L., Yang, Y., Mao, B., & Zheng, L. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0089 · Cited by 34
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype
Angius, A., Cossu‐Rocca, P., Arru, C., Muroni, M. R., Rallo, V., Carru, C., Uva, P., Pira, G., Orrù, S., & Miglio, M. R. D. (2020) · Cancers · doi:10.3390/cancers12113298 · Cited by 32
Li, D., Tao, Z., Wang, B., Wang, L., Cao, J., Hu, X., & Zhang, J. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00462-6 · Cited by 32
A Review of the Advancements in Targeted Therapies for Breast Cancer
Jallah, J. K., Dweh, T. J., Anjankar, A. P., & Palma, O. (2023) · Cureus · doi:10.7759/cureus.47847 · Cited by 35
PARP Inhibitors in Breast Cancer: a Short Communication
Daly, G. R., Alrawashdeh, M. M., McGrath, J., Dowling, G. P., Cox, L., Naidoo, S., Varešlija, D., Hill, A. D. K., & Young, L. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-023-01488-0 · Cited by 33
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology
Mazzeo, R., Sears, J., Palmero, L., Bolzonello, S., Davis, A. A., Gerratana, L., & Puglisi, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103700 · Cited by 34
Morigi, C. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.924 · Cited by 31
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer
Savard, M.-F., Khan, O. F., Hunt, K. K., & Verma, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237419 · Cited by 31
Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer
Yu, Y., Durairaj, C., Shi, H., & Wang, D. D. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1520 · Cited by 31
Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
Zeng, J., Johnson, A. M., Shufean, M. A., Kahle, M., Yang, D., Woodman, S. E., Vu, T., Moorthy, S., Holla, V. R., & Meric‐Bernstam, F. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00089 · Cited by 31
PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost
Hennes, E. R., Dow-Hillgartner, E. N., Bergsbaken, J., & Piccolo, J. K. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219895066 · Cited by 31
Liu, J., Adhav, R., Miao, K., Su, S. M., Mo, L., Chan, U. I., Zhang, X., Xu, J., Li, J., Shu, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18637-9 · Cited by 32
Owonikoko, T. K., Redman, M. W., Byers, L. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Bradley, J. D., Stinchcombe, T. E., Leighl, N. B., Baghdadi, T. A., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.001 · Cited by 31
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
Huang, R. S. P., Haberberger, J., McGregor, K., Mata, D. A., Decker, B. J., Hiemenz, M., Lechpammer, M., Danziger, N. A., Schiavone, K., Creeden, J., et al. (2021) · The Oncologist · doi:10.1002/onco.13855 · Cited by 32
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies
Sakach, E. A., O'Regan, R. M., Meisel, J. L., & Li, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.09.003 · Cited by 33
Metadata
- Authors
- Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y.-H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L.
- Affiliations
- Kaiser Permanente (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) — both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) — all in California; the...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-23
- Volume
- 379
- Issue
- 8
- Pages
- 753-763
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10600918
- OpenAlex
- W2886477543
- Cited by
- 2,175
- References
- 14
- Citations by year
- 2026: 195 · 2025: 241 · 2024: 254 · 2023: 312 · 2022: 356 · 2021: 319 · 2020: 280 · 2019: 195 · 2018: 20
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- PARP inhibitors, advanced breast cancer, germline BRCA1 mutation, germline BRCA2 mutation, progression-free survival, objective response rate, hematologic adverse events, anemia, patient-reported outcomes, quality of life, single-agent chemotherapy, capecitabine, eribulin, gemcitabine, vinorelbine, PARP inhibitor resistance, PARP inhibitor combination therapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Patient Reported Outcome Measures, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Phthalazines, Quality of Life, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
